Literature DB >> 21255596

Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats.

Keiichiro Sato1, Yasuyuki Awasaki, Hitoshi Kandori, Zen-Yo Tanakamaru, Hirofumi Nagai, David Baron, Masaki Yamamoto.   

Abstract

Pioglitazone hydrochloride (PIO), a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, was administered orally for 85 weeks at 16 mg/kg/day to male rats fed either a diet containing 1.5% ammonium chloride (acid-forming diet) or a control diet to investigate the effects of urinary acidification induced by the acid-forming diet on the tumorigenic potential of PIO in the urinary bladder. The surviving animals at the end of the administration period were followed to the end of the 2-year study period without changes in the diet and were subjected to terminal necropsy on Week 104. The number of urinary microcrystals, evaluated by manual counting with light microscopy and by an objective method with a laser diffraction particle size analyzer, was increased by PIO on Weeks 12 and 25 and the increases were markedly suppressed by urinary acidification. Urinary citrate was decreased by PIO throughout the study period, but no changes were seen in urinary oxalate at any timepoint. The incidences of PIO-treated males bearing at least one of the advanced proliferative changes consisting of papillary hyperplasia, nodular hyperplasia, papilloma or carcinoma were significantly decreased from 11 of 82 males fed the control diet to 2 of 80 males fed the acid-forming diet. The acid-forming diet did not show any effects on the toxicokinetic parameters of PIO and its metabolites. Microcrystalluria appears to be involved in the development of the advanced stage proliferative lesions in bladder tumorigenesis induced by PIO in male rats.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255596     DOI: 10.1016/j.taap.2011.01.006

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  16 in total

Review 1.  Pharmacological Modulation of Lung Carcinogenesis in Smokers: Preclinical and Clinical Evidence.

Authors:  Silvio De Flora; Gancho Ganchev; Marietta Iltcheva; Sebastiano La Maestra; Rosanna T Micale; Vernon E Steele; Roumen Balansky
Journal:  Trends Pharmacol Sci       Date:  2015-12-23       Impact factor: 14.819

2.  Stay vigilant: a glitazone (pioglitazone) can hide a glitazar!

Authors:  Dominique Hillaire-Buys; Jean-Luc Faillie; Jean-Louis Montastruc; Pierre Petit
Journal:  Eur J Clin Pharmacol       Date:  2012-05-11       Impact factor: 2.953

3.  Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case–control study.

Authors:  Fei-Yuan Hsiao; Pei-Hua Hsieh; Weng-Foung Huang; Yi-Wen Tsai; Churn-Shiouh Gau
Journal:  Drug Saf       Date:  2013-08       Impact factor: 5.606

4.  Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis.

Authors:  Richard M Turner; Chun S Kwok; Chen Chen-Turner; Chinedu A Maduakor; Sonal Singh; Yoon K Loke
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

5.  Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.

Authors:  Shiyao He; Yu-hong Tang; Guobin Zhao; Xiaolong Yang; Dehou Wang; Ye Zhang
Journal:  Tumour Biol       Date:  2013-10-04

6.  DNA damage in exfoliated cells and histopathological alterations in the urinary tract of mice exposed to cigarette smoke and treated with chemopreventive agents.

Authors:  Sebastiano La Maestra; Rosanna T Micale; Silvio De Flora; Francesco D'Agostini; Gancho Ganchev; Marietta Iltcheva; Nikolay Petkov; Vernon E Steele; Roumen Balansky
Journal:  Carcinogenesis       Date:  2012-10-05       Impact factor: 4.944

7.  Relationships between pulmonary micro-RNA and proteome profiles, systemic cytogenetic damage and lung tumors in cigarette smoke-exposed mice treated with chemopreventive agents.

Authors:  Alberto Izzotti; Roumen Balansky; Francesco D'Agostini; Mariagrazia Longobardi; Cristina Cartiglia; Sebastiano La Maestra; Rosanna T Micale; Anna Camoirano; Gancho Ganchev; Marietta Iltcheva; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2013-05-24       Impact factor: 4.944

Review 8.  Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis.

Authors:  Cristina Bosetti; Valentina Rosato; Danilo Buniato; Antonella Zambon; Carlo La Vecchia; Giovanni Corrao
Journal:  Oncologist       Date:  2013-01-23

Review 9.  Scientific Evidence and Controversies About Pioglitazone and Bladder Cancer: Which Lessons Can Be Drawn?

Authors:  Jean-Luc Faillie; Pierre Petit; Jean-Louis Montastruc; Dominique Hillaire-Buys
Journal:  Drug Saf       Date:  2013-09       Impact factor: 5.606

Review 10.  Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

Authors:  Raymond E Soccio; Eric R Chen; Mitchell A Lazar
Journal:  Cell Metab       Date:  2014-09-18       Impact factor: 27.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.